AU2016210548B2 - Cytomegalovirus antigens and uses thereof - Google Patents

Cytomegalovirus antigens and uses thereof Download PDF

Info

Publication number
AU2016210548B2
AU2016210548B2 AU2016210548A AU2016210548A AU2016210548B2 AU 2016210548 B2 AU2016210548 B2 AU 2016210548B2 AU 2016210548 A AU2016210548 A AU 2016210548A AU 2016210548 A AU2016210548 A AU 2016210548A AU 2016210548 B2 AU2016210548 B2 AU 2016210548B2
Authority
AU
Australia
Prior art keywords
leu
val
pro
ala
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016210548A
Other languages
English (en)
Other versions
AU2016210548A1 (en
Inventor
Andrea Carfi
Claudio CIFERRI
Yi Xing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of AU2016210548A1 publication Critical patent/AU2016210548A1/en
Priority to AU2018226521A priority Critical patent/AU2018226521B2/en
Application granted granted Critical
Publication of AU2016210548B2 publication Critical patent/AU2016210548B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/082—Hepadnaviridae (F), e.g. hepatitis B virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2016210548A 2015-01-22 2016-01-22 Cytomegalovirus antigens and uses thereof Ceased AU2016210548B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018226521A AU2018226521B2 (en) 2015-01-22 2018-09-10 Cytomegalovirus antigens and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15152221.6A EP3048114A1 (en) 2015-01-22 2015-01-22 Cytomegalovirus antigens and uses thereof
EP15152221.6 2015-01-22
PCT/IB2016/050335 WO2016116904A1 (en) 2015-01-22 2016-01-22 Cytomegalovirus antigens and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018226521A Division AU2018226521B2 (en) 2015-01-22 2018-09-10 Cytomegalovirus antigens and uses thereof

Publications (2)

Publication Number Publication Date
AU2016210548A1 AU2016210548A1 (en) 2017-08-10
AU2016210548B2 true AU2016210548B2 (en) 2018-11-08

Family

ID=52434568

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016210548A Ceased AU2016210548B2 (en) 2015-01-22 2016-01-22 Cytomegalovirus antigens and uses thereof
AU2018226521A Ceased AU2018226521B2 (en) 2015-01-22 2018-09-10 Cytomegalovirus antigens and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018226521A Ceased AU2018226521B2 (en) 2015-01-22 2018-09-10 Cytomegalovirus antigens and uses thereof

Country Status (24)

Country Link
US (2) US10167321B2 (https=)
EP (3) EP3048114A1 (https=)
JP (1) JP6717836B2 (https=)
KR (1) KR20170100039A (https=)
CN (1) CN107531761B (https=)
AU (2) AU2016210548B2 (https=)
BE (1) BE1023087B1 (https=)
BR (1) BR112017015567A2 (https=)
CA (1) CA2974041C (https=)
DK (1) DK3247722T5 (https=)
EA (1) EA038250B1 (https=)
ES (1) ES2937959T3 (https=)
FI (1) FI3247722T3 (https=)
HR (1) HRP20230177T1 (https=)
HU (1) HUE061175T2 (https=)
IL (1) IL253366B (https=)
LT (1) LT3247722T (https=)
MX (1) MX382518B (https=)
PL (1) PL3247722T3 (https=)
PT (1) PT3247722T (https=)
SG (1) SG11201705740UA (https=)
SI (1) SI3247722T1 (https=)
WO (1) WO2016116904A1 (https=)
ZA (1) ZA201704912B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3351636T (pt) * 2010-05-14 2020-09-24 Univ Oregon Health & Science Vectores de hcmv e rhcmv recombinantes codificadores de um antigénio heterólogo isolado a partir de um vírus paramyxoviridae e seus usos
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR102403547B1 (ko) 2014-07-16 2022-05-30 오레곤 헬스 앤드 사이언스 유니버시티 외인성 항원을 포함하는 인간 시토메갈로바이러스
JP6816031B2 (ja) 2015-02-10 2021-01-20 オレゴン ヘルス アンド サイエンス ユニバーシティ 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物
EP3324979B1 (en) 2015-07-21 2022-10-12 ModernaTX, Inc. Infectious disease vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
EP3364981A4 (en) 2015-10-22 2019-08-07 ModernaTX, Inc. VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
AU2016355468B2 (en) 2015-11-20 2022-12-15 Oregon Health & Science University CMV vectors comprising microRNA recognition elements
US11318197B2 (en) 2016-03-03 2022-05-03 Duke University Compositions and methods for inducing HIV-1 antibodies
US11246920B2 (en) 2016-03-03 2022-02-15 Duke University Compositions and methods for inducing HIV-1 antibodies
EP3519428A4 (en) 2016-10-03 2020-07-08 Duke University METHODS OF IDENTIFYING IMMUNOGENS BY TARGETING IMPROBABLE MUTATIONS
CN110036112B (zh) 2016-10-18 2024-05-10 俄勒冈健康与科学大学 引发受主要组织相容性复合体e分子限制的t细胞的巨细胞病毒载体
MA46584A (fr) 2016-10-21 2019-08-28 Modernatx Inc Vaccin contre le cytomégalovirus humain
WO2018151816A1 (en) 2017-02-16 2018-08-23 Modernatx, Inc. High potency immunogenic compositions
CA3060019A1 (en) * 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
US11773144B2 (en) 2017-10-02 2023-10-03 Duke University Mosaic HIV-1 envelopes to induce ADCC responses
CA3095216A1 (en) 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
CN112512566A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性爱泼斯坦-巴尔病毒多肽
US12138304B2 (en) 2018-10-01 2024-11-12 Duke University HIV-1 envelope stabilizing mutations
CA3116175A1 (en) 2018-10-17 2020-04-23 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
CN109627330A (zh) * 2018-12-18 2019-04-16 马鞍山史记动物健康管理有限公司 一种猪伪狂犬病毒高效价阳性血清制备方法
EP3938379A4 (en) 2019-03-15 2023-02-22 ModernaTX, Inc. Hiv rna vaccines
EP4004018A1 (en) 2019-07-24 2022-06-01 GlaxoSmithKline Biologicals SA Modified human cytomegalovirus proteins
TWI810589B (zh) * 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
US20250101067A1 (en) 2022-01-28 2025-03-27 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
CN118480118B (zh) * 2022-10-21 2025-08-19 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014005959A1 (en) * 2012-07-06 2014-01-09 Novartis Ag Complexes of cytomegalovirus proteins

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ATE174058T1 (de) 1989-11-06 1998-12-15 Cell Genesys Inc Herstellung von proteinen mittels homologer rekombination
EP3031469B1 (en) 2006-06-07 2023-08-23 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
PE20141435A1 (es) * 2008-07-16 2014-10-22 Inst Research In Biomedicine Anticuerpos neutralizantes de citomegalovirus humano
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
EP2590625B1 (en) 2010-07-06 2017-09-20 GlaxoSmithKline Biologicals SA Cationic oil-in-water emulsions
JP2013544504A (ja) 2010-10-11 2013-12-19 ノバルティス アーゲー 抗原送達プラットフォーム
CA2840965C (en) 2011-07-06 2021-03-02 Novartis Ag Cationic oil-in-water emulsions
TWI570240B (zh) * 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
MX2015005505A (es) * 2012-10-30 2016-01-08 Redvax Gmbh Vacunas basadas en particular recombinantes contra la infeccion de citomegalovirus humano.
ES2758505T3 (es) 2013-12-20 2020-05-05 Novartis Ag Células eucariotas novedosas y métodos para expresar de forma recombinante un producto de interés
WO2015092735A1 (en) 2013-12-20 2015-06-25 Novartis Ag Novel eukaryotic cells and methods for recombinantly expressing a product of interest
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
EP3047856A1 (en) 2015-01-23 2016-07-27 Novartis AG Cmv antigens and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014005959A1 (en) * 2012-07-06 2014-01-09 Novartis Ag Complexes of cytomegalovirus proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLAUDIO CIFERRI ET AL, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (2015-01-26), vol. 112, no. 6, doi:10.1073/pnas.1424818112, ISSN 0027-8424, pages 1767 - 1772 *
RYCKMAN BRENT J ET AL,, JOURNAL OF VIROLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 82, no. 1, doi:10.1128/JVI.01910-07, ISSN 1098-5514, (2008-01-01), pages 60 - 70, (2007-10-17) *
WEN YINGXIA ET AL, , VACCINE, ELSEVIER LTD, GB, (2014-05-14), vol. 32, no. 30, doi:10.1016/J.VACCINE.2014.05.004, ISSN 0264-410X, pages 3796 - 3804 *

Also Published As

Publication number Publication date
HUE061175T2 (hu) 2023-05-28
US20170369532A1 (en) 2017-12-28
IL253366A0 (en) 2017-09-28
JP6717836B2 (ja) 2020-07-08
PT3247722T (pt) 2023-01-31
KR20170100039A (ko) 2017-09-01
US10167321B2 (en) 2019-01-01
DK3247722T5 (da) 2024-10-07
EP3247722A1 (en) 2017-11-29
AU2018226521B2 (en) 2019-10-31
EP4180056A1 (en) 2023-05-17
BE1023087B1 (fr) 2016-11-18
MX382518B (es) 2025-03-13
EA201791562A1 (ru) 2018-04-30
FI3247722T3 (fi) 2023-03-17
HRP20230177T1 (hr) 2023-04-14
DK3247722T3 (da) 2023-01-30
BR112017015567A2 (pt) 2018-03-13
CN107531761B (zh) 2022-01-14
IL253366B (en) 2022-03-01
EP3048114A1 (en) 2016-07-27
CA2974041A1 (en) 2016-07-28
LT3247722T (lt) 2023-02-10
SI3247722T1 (sl) 2023-04-28
AU2018226521A1 (en) 2018-09-27
AU2016210548A1 (en) 2017-08-10
CN107531761A (zh) 2018-01-02
JP2018504117A (ja) 2018-02-15
EP3247722B1 (en) 2022-11-30
BE1023087A1 (fr) 2016-11-18
MX2017009538A (es) 2017-11-02
US20190276498A1 (en) 2019-09-12
CA2974041C (en) 2023-04-04
PL3247722T3 (pl) 2023-03-20
ES2937959T3 (es) 2023-04-03
WO2016116904A1 (en) 2016-07-28
EA038250B1 (ru) 2021-07-29
SG11201705740UA (en) 2017-08-30
ZA201704912B (en) 2018-12-19

Similar Documents

Publication Publication Date Title
AU2018226521B2 (en) Cytomegalovirus antigens and uses thereof
EP3031822A1 (en) Cytomegalovirus antigens
CN113151184A (zh) 基于细胞膜展示冠状病毒免疫原以诱导中和抗体的方法
US20210346492A1 (en) SARS-CoV-2 Vaccines
WO2015181142A1 (en) Cytomegalovirus complexes and uses thereof
JP2023523423A (ja) ＳＡＲＳ－ＣｏＶ－２に対するワクチン及びその調製物
KR20230008707A (ko) 코로나바이러스 치료용 백신 조성물
CA2944230A1 (en) Human cytomegalovirus vaccine compositions and method of producing the same
US20250026793A1 (en) Chimeric betacoronavirus spike polypeptides
WO2023236822A1 (zh) H5n6禽流感广谱性疫苗的开发及其应用
HK40087930A (en) Cytomegalovirus antigens and uses thereof
KR100845192B1 (ko) Ｇｍ-음성 ｅｈｖ-돌연변이
WO2023179514A1 (zh) 冠状病毒疫苗组合物、方法及其使用
WO2023179513A1 (zh) 冠状病毒疫苗组合物、方法及其使用
WO2023047349A1 (en) Stabilized coronavirus spike protein fusion proteins
JP2023549787A (ja) キメラコロナウイルススパイクタンパク質をコードする組換えベクターおよびその使用
CN116685347A (zh) 编码嵌合冠状病毒刺突蛋白的重组载体及其用途
WO2023047348A1 (en) Stabilized corona virus spike protein fusion proteins
EP4722230A1 (en) Coronavirus vaccine composition, method therefor and use thereof
TW202320845A (zh) 用於預防及治療２０１９冠狀病毒病（ＣＯＶＩＤ—１９）之ＳＡＲＳ—ＣｏＶ—２多重表位肽／蛋白質疫苗
Wang Expression and Characterization of SARS Spike and Nucleocapsid Proteins and Their Fragments in Baculovirus and E. coli
HK1012415B (en) Fusion glycoprotein from hcmv and hsv
HK1012415A1 (en) Fusion glycoprotein from hcmv and hsv

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired